WebMD not in acquisition talks

Despite being the subject of acquisition rumors, WebMD Health said it is not currently in any negotiations to be acquired.

"In light of recent news reports, the company is reporting that it is not currently in any negotiations to be acquired," WebMD said in a press release.

Before the announcement, WebMD stock was up more than 9 percent. Afterward, its stock was down more than 7 percent. Overall, WebMD stock has risen 31 percent since September.

The Financial Times reported the potential acquisition talks with Walgreens Boots Alliance and UnitedHealth Group, among other potential buyers. WedMD looked into putting itself up for sale in 2015, but eventually opted out.

Walgreens has completed several acquistions over the past few months, including the Alliance Boots takeover and the purchase of Rite Aid. The Rite Aid buy is a multi-million dollar deal that still has to complete anti-trust review.

New York-based WebMD has a market value of just under $2 billion. The WebMD Health Network includes WebMD.com, Medscape.com, MedicineNet.com, eMedicineHealth.com, RxList.com, Medscape Education and other WebMD-owned sites and apps.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.